Artelo Biosciences Presents Significant Findings at the Summit
Artelo Biosciences, Inc. (NASDAQ: ARTL), a pharmaceutical firm specialized in lipid-signaling pathways, recently announced promising results from clinical studies involving their drug candidates, ART26.12 and ART27.13. These groundbreaking presentations took place at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit.
Positive Outcomes from ART26.12
During the event, Professor Saoirse O'Sullivan, the Vice President of Translational Sciences, presented key insights on ART26.12, Artelo’s leading Fatty Acid Binding Protein 5 (FABP5) inhibitor. The Phase 1 data demonstrated no safety concerns, with predictable linear plasma exposure noted. Furthermore, the drug maintained dosing flexibility, being effective in both fed and fasted states, showcasing its potential as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy.
Exploring Dosing Flexibility
The findings from the Single Ascending Dose (SAD) study were particularly encouraging. It indicated that doses up to 1050 milligrams were well tolerated among healthy volunteers. These results laid the foundation for future studies, which Artelo believes will support the advancement of ART26.12 into further phases, including multiple ascending doses and initial pain study trials.
Insights on ART27.13 Development
In conjunction with discussions on ART26.12, Professor O'Sullivan also shed light on ART27.13’s progress, focusing on its development for cancer-related anorexia. The interim Phase 2 data from the Cancer Appetite Recovery Study (CAReS) revealed that participants utilizing ART27.13 experienced an impressive weight gain compared to those receiving a placebo, highlighting the drug's beneficial effects.
Addressing Cancer-Related Anorexia
In the Phase 2 trial, patients administered an average of 1300 micrograms daily gained over 6% in weight while those on placebo lost additional weight. Importantly, even with higher dosing, the safety profile remained similar to the initial Phase 1 study, indicating that ART27.13 could be an essential player in the fight against cancer anorexia, a condition affecting up to 80% of late-stage cancer patients.
Leadership in Cannabinoid Research
Professor O'Sullivan expressed her enthusiasm about the advancements made in cannabinoid therapeutics, recognizing the potential life-changing impacts on patients dealing with pain and anorexia. The rigorous scientific approach taken by Artelo and its commitment to address pressing medical needs were highlighted, showcasing the dedication of their team to improving patient care.
About Artelo Biosciences
Artelo Biosciences, Inc. is not just focused on oncology but has a diversified pipeline aiming to alleviate conditions related to cancer, pain, and anxiety disorders. The company continues to develop novel therapeutics that modulate lipid-signaling pathways through rigorous clinical research and partnerships with leading experts in the field.
Future Prospects
As Artelo Biosciences promotes its pioneering research in cannabinoid therapies, it remains poised to make significant contributions to treating conditions that currently lack approved therapies. Artelo’s innovative approaches highlight the vital intersection of scientific research and patient care, thereby promising a brighter future for individuals suffering from severe health conditions.
Frequently Asked Questions
What is ART26.12 and what are its benefits?
ART26.12 is a FABP5 inhibitor designed to treat chemotherapy-induced peripheral neuropathy, with demonstrated safety and dosing flexibility in trials.
What were the findings presented at the Cannabinoid Summit?
Artelo presented positive clinical data for both ART26.12 and ART27.13, highlighting their potential in treating cancer-related anorexia and peripheral neuropathic pain.
How does ART27.13 differ from ART26.12?
ART27.13 is a dual cannabinoid agonist focusing on improving appetite and weight in cancer patients, while ART26.12 targets pain relief.
What are the next steps for Artelo Biosciences?
Artelo plans to advance both ART26.12 and ART27.13 into further clinical trials, targeting multifaceted therapeutic applications for cancer patients.
Who can I contact for more information about Artelo?
For more details, you can reach out to Crescendo Communications at 212-671-1020 or via email at ARTL@crescendo-ir.com.
